Quantcast
Viewing all articles
Browse latest Browse all 1678

Quinupramine, キヌプラミン

Image may be NSFW.
Clik here to view.
Quinupramine

Quinupramine

キヌプラミン

  • 5-(1-azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine
  • Formula:C21H24N2
  • MW:304.44 g/mol
  • CAS:31721-17-2
Quinupramine
CAS Registry Number: 31721-17-2
CAS Name: 5-(1-Azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine
Additional Names: 10,11-dihydro-5-(3-quinuclidinyl)-5H-dibenz[b,f]azepine
Manufacturers’ Codes: LM-208
Trademarks: Kinupril (Bellon); Kevopril (Rhone-Poulenc)
Molecular Formula: C21H24N2
Molecular Weight: 304.43
Percent Composition: C 82.85%, H 7.95%, N 9.20%
Literature References: Analog of imipramine, q.v. Prepn: C. Gueremy, P. C. Wirth, DE 2030492 (1971 to Sogeras), C.A. 74,141581e (1971). Animal studies: W. Van Dorsser, A. Dresse, Arch. Int. Pharmacodyn. Ther. 208, 373 (1974); eidem, ibid. 220, 164 (1976). Clinical study: R. Volmat et al., Clin. Neurol. Psychiat. 239, 445 (1978).
Properties: Crystals, mp 150°.
Melting point: mp 150°
Therap-Cat: Antidepressant.
Keywords: Antidepressant; Tricyclics.

Quinupramine (brand names KevoprilKinuprilAdeprimQuinuprine) is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.[1][2]

Pharmacologically, quinupramine acts in vitro as a strong muscarinic acetylcholine receptor antagonist (anticholinergic) and H1 receptorantagonist (antihistamine), moderate 5-HT2 receptor antagonist, and weak serotonin and norepinephrine reuptake inhibitor.[3] It has negligible affinity for the α1-adrenergicα2-adrenergicβ-adrenergic, or D2 receptor.[3]

Clinically, quinupramine is reported to be stimulating similarly to imipraminedesipramine, and demexiptiline.[4] It can be inferred that its in vivo metabolites may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself

SYN

Image may be NSFW.
Clik here to view.

References

  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 908. ISBN 3-88763-075-0.
  2. ^ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 248. ISBN 978-3-527-31058-6.
  3. Jump up to:a b Sakamoto H, Yokoyama N, Kohno S, Ohata K (December 1984). “Receptor binding profile of quinupramine, a new tricyclic antidepressant”. Japanese Journal of Pharmacology36 (4): 455–60. doi:10.1254/jjp.36.455PMID 6098759.
  4. ^ Kent, Angela; M. Billiard (2003). Sleep: physiology, investigations, and medicine. New York: Kluwer Academic/Plenum. p. 233. ISBN 0-306-47406-9.
    • DOS 2 030 492 (Sogeras; appl. 20.6.1970; GB-prior. 20.6.1969).
    • GB 1 252 320 (Sogeras; valid from 29.5.1970; prior. 20.6.1969).
Quinupramine
Image may be NSFW.
Clik here to view.
Quinupramine.svg
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life 33 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.046.149 Image may be NSFW.
Clik here to view.
Edit this at Wikidata
Chemical and physical data
Formula C21H24N2
Molar mass 304.43 g/mol g·mol−1

//////////////Quinupramine, キヌプラミン


Viewing all articles
Browse latest Browse all 1678

Trending Articles